8-K: Surgery Partners Reports Q1 2026 Results, Reaffirms Guidance

Surgery Partners announced its first quarter 2026 financial results, reporting a 4.5% increase in revenue and reaffirming its full-year guidance.

Summary

• Surgery Partners reported first quarter 2026 revenue of $810.9 million, a 4.5% increase compared to the same period in 2025.
• Same-facility revenues grew by 4.4%, driven by a 3.8% increase in revenue per case and a 0.6% increase in same-facility cases.
• The company reported a net loss attributable to Surgery Partners, Inc. of $35.9 million for the quarter.
• Adjusted EBITDA for the first quarter was $102.3 million, a slight decrease from $103.9 million in the prior year.
• Full-year 2026 revenue guidance remains between $3.35 billion and $3.45 billion, with Adjusted EBITDA expected to be at least $530 million.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive report, with solid revenue growth and reaffirmed guidance offset by a net loss and a slight dip in Adjusted EBITDA margin.

Positives

• Revenue increased by 4.5% to $810.9 million in Q1 2026.
• Same-facility revenues showed a solid increase of 4.4%.
• Revenue per case increased by 3.8%.
• The company reaffirmed its full-year 2026 revenue guidance of $3.35 billion to $3.45 billion.
• Full-year 2026 Adjusted EBITDA guidance is reaffirmed at a minimum of $530 million.
• Cash flows from operating activities improved to $11.7 million from $6.0 million in the prior year's first quarter.
• Borrowing capacity under the revolving credit facility was $666.1 million as of March 31, 2026.

Negatives

• The company reported a net loss attributable to Surgery Partners, Inc. of $35.9 million for the first quarter of 2026.
• Adjusted EBITDA decreased slightly to $102.3 million from $103.9 million in Q1 2025.
• Adjusted EBITDA margin decreased to 12.6% from 13.4% in the prior year.

Risks

• Reductions in payments from government health care programs and private insurance payors.
• Ability to contract with private insurance payors.
• Changes in payor mix or surgical case mix.
• Failure to maintain or develop relationships with physicians.
• Impact of payor controls designed to reduce surgical procedures.
• Supply chain issues, including shortages or quality control issues with surgery-related products.
• Competition for physicians, nurses, strategic relationships, acquisitions, and managed care contracts.
• Ability to attract and retain qualified health care professionals.

Future Outlook

The company reaffirmed its full-year 2026 revenue guidance to be in the range of $3.35 billion to $3.45 billion and Adjusted EBITDA of at least $530 million. Management expressed confidence in returning to their growth algorithm through capitalizing on market opportunities, driving operational excellence, and thoughtful capital deployment.

Management Comments

• "We are encouraged by our solid start to 2026, with same store revenue growth of 4.4% in line with our Q1 and long-term growth expectations."
• "As we continue to navigate near-term market dynamics, our cost management discipline and continued execution on physician recruitment position us well to meet or exceed our 2026 plan."
• "The results we reported today were in line with expectations and reinforce our confidence in reaffirming our guidance for the full year."
• "We are beginning to see improvements, and we continue to believe in the strong fundamentals underpinning our business."
• "Through disciplined execution, and a continued focus on improving free cash flow and reducing leverage, we are well-positioned to return the business to consistent growth, while delivering on long-term shareholder value."

Industry Context

StockSavvy.ai notes that Surgery Partners' Q1 2026 results reflect the ongoing trends in the outpatient surgical facility market, characterized by steady revenue growth driven by increased case volumes and revenue per case, while managing profitability amidst operational costs. The reaffirmation of guidance suggests management's confidence in sustained performance despite near-term market dynamics.

Comparison to Industry Standards

• The reported same-facility revenue growth of 4.4% aligns with the company's long-term growth expectations and is generally in line with industry benchmarks for established outpatient surgical providers.
• The increase in revenue per case by 3.8% indicates effective pricing strategies or a shift towards higher-reimbursement procedures, a positive trend observed across the sector.
• The slight decrease in Adjusted EBITDA margin from 13.4% to 12.6% may be influenced by factors such as increased operating expenses or investments in growth initiatives, which are common in the competitive healthcare services landscape.

Legal Proceedings

• The company mentions litigation settlements and other litigation costs in its financial statements and reconciliations, but no specific new proceedings are detailed in this filing.

Stakeholder Impact

• Shareholders: Reaffirmed guidance and steady revenue growth may be viewed positively, but the net loss and slight EBITDA margin decrease could be a concern.
• Employees: Continued focus on operational excellence and physician recruitment suggests a stable or growing operational environment.
• Physicians: Emphasis on physician recruitment and maintaining relationships is critical for the company's operating model.
• Payors: The company's ability to contract with private insurance payors and manage payor mix is a key factor impacting revenue.

Next Steps

• Continue to execute on cost management discipline.
• Continue execution on physician recruitment.
• Continue portfolio optimization efforts.
• Focus on improving free cash flow.
• Focus on reducing leverage.

Key Dates

Recommendation

The company demonstrated steady revenue growth and reaffirmed its full-year guidance, indicating performance is in line with expectations. However, the reported net loss and a slight decrease in Adjusted EBITDA margin suggest that while the business is stable, significant upside catalysts are not immediately apparent from this filing alone. A 'hold' recommendation is appropriate pending further operational improvements or clearer signs of accelerated growth.

Keywords

Surgery Partners, 8-K, Q1 2026, Earnings, Revenue, Adjusted EBITDA, Healthcare Services, Financial Results